Cargando…

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

BACKGROUND: Expression of Bcr-Abl in hematopoietic stem cells is sufficient to cause chronic myeloid leukemia (CML) and tyrosine kinase inhibitors (TKI) induce molecular remission in the majority of CML patients. However, the disease driving stem cell population is not fully targeted by TKI therapy,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrmann, Oliver, Kuepper, Maja Kim, Bütow, Marlena, Costa, Ivan G., Appelmann, Iris, Beier, Fabian, Luedde, Tom, Braunschweig, Till, Koschmieder, Steffen, Brümmendorf, Tim H., Schemionek, Mirle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610865/ https://www.ncbi.nlm.nih.gov/pubmed/31272418 http://dx.doi.org/10.1186/s12885-019-5871-2

Ejemplares similares

Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
por: Parting, Oliver, et al.
Publicado: (2020)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition
por: Bütow, Marlena, et al.
Publicado: (2022)

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients
por: Schubert, Claudia, et al.
Publicado: (2017)

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
por: Han, Lijuan, et al.
Publicado: (2016)

XBP1 promotes NRAS(G12D) pre‐B acute lymphoblastic leukaemia through IL‐7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS
por: Salimi, Azam, et al.
Publicado: (2023)

P653: CML LONG-TERM LEUKEMIC STEM CELL PERSISTENCE IS INFLUENCED BY MYELOFIBROSIS AT DIAGNOSIS
por: Jacobi, Henrike, et al.
Publicado: (2023)

Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK
por: Salimi, Azam, et al.
Publicado: (2022)

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
por: Jacobi, Henrike, et al.
Publicado: (2023)

Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia
por: Vieri, Margherita, et al.
Publicado: (2023)

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN
por: Tillmann, Stefan, et al.
Publicado: (2021)

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
por: Schubert, Claudia, et al.
Publicado: (2019)

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia
por: Schemionek, Mirle, et al.
Publicado: (2015)

Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia
por: Jost, E, et al.
Publicado: (2014)

Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing
por: Kirschner, Martin M. J., et al.
Publicado: (2015)

Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells
por: Lipka, Daniel B., et al.
Publicado: (2012)

Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
por: Langhammer, Melanie, et al.
Publicado: (2023)

Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas
por: Ventura Ferreira, Monica S., et al.
Publicado: (2018)

KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile
por: de Toledo, Marcelo A. S., et al.
Publicado: (2023)

Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
por: Gorgulho, Joao, et al.
Publicado: (2023)

Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia
por: Brehme, Marc, et al.
Publicado: (2016)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Whether innate immune together with genetic factor are involved in leukemic arthritis?: A case report and review of the literature
por: Xu, Danyi, et al.
Publicado: (2018)

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study
por: Manz, Kirsi, et al.
Publicado: (2023)

Comprehensive characterization of chorionic villi-derived mesenchymal stromal cells from human placenta
por: Ventura Ferreira, Mónica S., et al.
Publicado: (2018)

Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature
por: Jennes, Eva, et al.
Publicado: (2017)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
por: Olschok, Kathrin, et al.
Publicado: (2023)

Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia
por: Muselli, Fabien, et al.
Publicado: (2023)

A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma
por: Metselaar, Josbert, et al.
Publicado: (2023)

Effect of Notch and PARP Pathways’ Inhibition in Leukemic Cells
por: Horvat, Luka, et al.
Publicado: (2018)

Changes of Dentition State in Leukemic Patients during Chemotherapy
por: Ptasiewicz, Maja, et al.
Publicado: (2021)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3
por: Zeyn, Yanira, et al.
Publicado: (2023)

Hematopoietic stem and progenitor cell proliferation and differentiation requires the trithorax protein Ash2l
por: Lüscher-Firzlaff, Juliane, et al.
Publicado: (2019)

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation
por: Chomel, Jean Claude, et al.
Publicado: (2016)

Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
por: Vieri, Margherita, et al.
Publicado: (2023)

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

The role of mitochondrial proteases in leukemic cells and leukemic stem cells
por: Mirali, Sara, et al.
Publicado: (2020)

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and “pan-leukemia” antigens
por: Backert, Linus, et al.
Publicado: (2017)

Coming together, keeping together, working together
por: Rochford, Diane
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gc66r4boohh9nbk4o83a4kmcl3